A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer

  Objective  To analyze the clinical effect of nitorzumab injection combined with concurrent chemoradiotherapy in the treatment of advanced esophageal cancer.

  Methods  The databases such as CNKI, Wanfang, VIP, China Biology Medicine (CBM), PubMed, Cochrane Library, Wiley Online Library and Google Academic were searched. The randomized controlled trials (RCT) of nituozumab combined with concurrent chemoradiotherapy (experimental group) and concurrent chemoradiotherapy (control group) were searched. The between-group differences of objective remission rate (ORR), disease control rate (DCR) and drug-related adverse reactions were analyzed by RevMan5.3 software.

  Results  Totally 9 studies were included, in which 8 studies were Chinese literatures and one study was foreign language literature. Meta-analysis showed that the ORR and DCR of the experimental group significantly improved and the incidence of adverse reactions was not increased.

  Conclusion  Efficacy and safety of nituozumab injection combined with concurrent chemoradiotherapy are reliable and definite. Rash and change of blood pressure may appear in the course of treatment, but the probability and the degree are relative low.